Cadrenal Therapeutics, Inc. Common Stock (CVKD) एक सार्वजनिक रूप से कारोबार करने वाली कंपनी है में स्वास्थ्य सेवा क्षेत्र, संचालन करती है Biotechnology उद्योग. कंपनी का मुख्यालय है Ponte Vedra, FL, United States. वर्तमान CEO हैं Quang X. Pham.
CVKD के पास है IPO तिथि 2023-01-20, 4 पूर्णकालिक कर्मचारी, पर सूचीबद्ध NASDAQ Global Market, बाजार पूंजीकरण $12.01M.
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
